# AstraZeneca’s Fasenra approved in the US for eosinophilic granulomatosis with polyangiitis

- Link: https://www.directorstalkinterviews.com/astrazenecas-fasenra-approved-in-the-us-for-eosinophilic-granulomatosis-with-polyangiitis/4121171435
- Published: 2024-09-18T07:37:31+01:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
_Fasenra_ (benralizumab) has been approved in the US for the treatment of adult 
patients with eosinophilic granulomatosis with polyangiitis (EGPA).^(1) EGPA is 
a rare, immune-mediated vasculitis that can result in damage to multiple organs,
and without treatment, can be fatal.^(2,3)

The approval by the US Food and Drug Administration (FDA) was based on positive 
results from the MANDARA Phase III trial published in The New England Journal of
Medicine,^(4) which compared the efficacy and safety of _Fasenra_ to the only approved
EGPA treatment, mepolizumab, in patients with relapsing or refractory EGPA.^(4-6)
MANDARA was the first head-to-head non-inferiority trial of biologics in patients
with EGPA.^(5,7) Patients were randomised to receive either a single 30 mg subcutaneous
injection of _Fasenra_, or three separate 100 mg subcutaneous injections of mepolizumab
every four weeks.^(4,5)

In the trial, nearly 60% of _Fasenra-_treated patients achieved remission which 
was comparable to mepolizumab-treated patients.^(4) Data also showed 41% of _Fasenra-
_treated patients fully tapered off oral corticosteroids (OCS) (vs. 26% in the mepolizumab
arm (difference: 16%; 95% CI: 1,31)).^(4)

> **Dr. Michael Wechsler, Professor of Medicine and Director of The Asthma Institute
> at National Jewish Health, and International Coordinating Investigator of the 
> MANDARA trial said**: “This approval is great news for patients with EGPA in the
> US who continue to suffer from debilitating symptoms. Patients often rely on long-
> term oral corticosteroids, which can cause serious and lasting side effects. Benralizumab
> is a much-needed treatment option, with data showing that not only is remission
> an achievable goal for EGPA patients, but benralizumab can also help patients 
> taper off steroid therapy.”

> **Joyce Kullman, Executive Director, Vasculitis Foundation said**: “This disease
> has a devastating impact on patients and the quality of their life, and they need
> more treatment options. The approval of another treatment in EGPA is welcome news
> to the approximately 15,000 patients living in the US with this difficult-to-treat
> rare disease.”

> **Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, AstraZeneca
> said**: “_Fasenra_ is already well established for the treatment of severe eosinophilic
> asthma, and with this approval, physicians in the US will now be able to offer
> an important new, convenient single monthly subcutaneous injection to their patients
> with EGPA. Today’s news demonstrates the potential of _Fasenra_ to help patients
> suffering from eosinophilic diseases beyond severe asthma.”

The safety and tolerability profile for _Fasenra_ in the MANDARA trial was consistent
with the known profile of the medicine.^(4)

Approximately half of patients with EGPA have adult-onset severe eosinophilic asthma(
SEA) and often have sinus and nasal symptoms.^(3,8,9) _Fasenra_ is only the second
biologic approved to treat this disease.^(4,5)

_Fasenra_ is currently approved as an add-on maintenance treatment for SEA in more
than 80 countries including the US, Japan, EU and China.^(10-13) It is also approved
in children and adolescents ages six and above in the US and Japan. The FDA granted
Orphan Drug Designation for _Fasenra_ for EGPA in 2018.^(14)

References

 1.  Fasenra (benralizumab) US prescribing information; September 2024.
 2.  Furuta S, et al. Update on eosinophilic granulomatosis with polyangiitis. Allergol
     Int. 2019;68:430-436.
 3.  American Partnership for Eosinophilic Disorders. Eosinophilic Granulomatosis with
     Polyangiitis (EGPA). Available at: https://apfed.org/about-ead/eosinophilic-granulomatosis-
     with-polyangiitis/. [Last accessed: September 2024].
 4.  Wechsler ME, et al. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis
     with Polyangiitis. N Engl J Med. 2024;390(10):911-921.
 5.  Clinicaltrials.gov. Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.(
     MANDARA). Available at: https://classic.clinicaltrials.gov/ct2/show/NCT04157348.[
     Last accessed: September 2024].
 6.  Mepolizumab US prescribing information. Available from: https://www.fda.gov/files/
     drugs/published/125526-Mepolizumab-Clinical-PREA.pdf [Last accessed: September
     2024].
 7.  AstraZeneca plc. MANDARA Phase III data published in New England Journal of Medicine
     show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis(
     EGPA) with Fasenra. Available at: https://www.astrazeneca.com/media-centre/medical-
     releases/mandara-phase-iii-data-published-new-england-journal-medicine-show-remission-
     achievable-goal-eosinophilic-granulomatosis-polyangiitis-egpa-fasenra.html. [Last
     accessed: September 2024].
 8.  Cottin V, et al. Respiratory manifestations of eosinophilic granulomatosis with
     polyangiitis (Churg-Strauss). Eur Respir J. 2016;48:1429-1441.
 9.  Heaney L et al. Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework
     to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort. Chest. 
     2021 Sep;160(3):814-830.
 10. AstraZeneca news release. Available at: https://www.astrazeneca.com/media-centre/
     press-releases/2019/fasenra-approved-in-the-us-for-self-administration-in-a-new-
     pre-filled-auto-injector-the-fasenra-pen-04102019.html#. [Last accessed: September
     2024].
 11. AstraZeneca news release. Available at: https://www.astrazeneca.com/media-centre/
     press-releases/2019/fasenra-receives-positive-eu-chmp-opinion-for-self-administration-
     and-the-new-fasenra-pen-a-pre-filled-single-use-auto-injector-01072019.html#. [
     Last accessed: September 2024].
 12. AstraZeneca Annual Report 2023. Available at: https://www.astrazeneca.com/content/
     dam/az/Investor_Relations/annual-report-2023/pdf/AstraZeneca_AR_2023.pdf. [Last
     accessed: September 2024].
 13. AstraZeneca news release. Fasenra met the primary endpoint in the MANDARA Phase
     III trial in eosinophilic granulomatosis with polyangiitis (EGPA). Available at:
     https://www.astrazeneca.com/media-centre/press-releases/2023/fasenra-phase-iii-
     egpa-trial-met-primary-endpoint.html#:~:text=Positive%20high%2Dlevel%20results%
     20from,EGPA)%20who%20were%20receiving%20oral. [Last accessed: September 2024].
 14. AstraZeneca news release. Available at: https://www.astrazeneca.com/media-centre/
     press-releases/2018/us-fda-grants-fasenra-orphan-drug-designation-for-eosinophilic-
     granulomatosis-with-polyangiitis-26112018.html.

Share on:
